JP2009268467A5 - - Google Patents

Download PDF

Info

Publication number
JP2009268467A5
JP2009268467A5 JP2009147075A JP2009147075A JP2009268467A5 JP 2009268467 A5 JP2009268467 A5 JP 2009268467A5 JP 2009147075 A JP2009147075 A JP 2009147075A JP 2009147075 A JP2009147075 A JP 2009147075A JP 2009268467 A5 JP2009268467 A5 JP 2009268467A5
Authority
JP
Japan
Prior art keywords
polypeptide
acid sequence
amino acid
helper cells
following
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009147075A
Other languages
English (en)
Japanese (ja)
Other versions
JP4969610B2 (ja
JP2009268467A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009268467A publication Critical patent/JP2009268467A/ja
Publication of JP2009268467A5 publication Critical patent/JP2009268467A5/ja
Application granted granted Critical
Publication of JP4969610B2 publication Critical patent/JP4969610B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2009147075A 1999-09-09 2009-06-19 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用 Expired - Lifetime JP4969610B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39309099A 1999-09-09 1999-09-09
US09/393,090 1999-09-09
US16461699P 1999-11-10 1999-11-10
US60/164,616 1999-11-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006231402A Division JP2007045830A (ja) 1999-09-09 2006-08-28 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010098317A Division JP2010233571A (ja) 1999-09-09 2010-04-21 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用

Publications (3)

Publication Number Publication Date
JP2009268467A JP2009268467A (ja) 2009-11-19
JP2009268467A5 true JP2009268467A5 (https=) 2010-07-01
JP4969610B2 JP4969610B2 (ja) 2012-07-04

Family

ID=26860707

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2001522273A Expired - Lifetime JP4505166B2 (ja) 1999-09-09 2000-09-08 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用
JP2006231402A Withdrawn JP2007045830A (ja) 1999-09-09 2006-08-28 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用
JP2009147075A Expired - Lifetime JP4969610B2 (ja) 1999-09-09 2009-06-19 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用
JP2010098317A Withdrawn JP2010233571A (ja) 1999-09-09 2010-04-21 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用
JP2013040389A Pending JP2013128489A (ja) 1999-09-09 2013-03-01 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用
JP2014206652A Expired - Fee Related JP6140122B2 (ja) 1999-09-09 2014-10-07 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2001522273A Expired - Lifetime JP4505166B2 (ja) 1999-09-09 2000-09-08 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用
JP2006231402A Withdrawn JP2007045830A (ja) 1999-09-09 2006-08-28 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2010098317A Withdrawn JP2010233571A (ja) 1999-09-09 2010-04-21 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用
JP2013040389A Pending JP2013128489A (ja) 1999-09-09 2013-03-01 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用
JP2014206652A Expired - Fee Related JP6140122B2 (ja) 1999-09-09 2014-10-07 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用

Country Status (15)

Country Link
EP (1) EP1210434B2 (https=)
JP (6) JP4505166B2 (https=)
KR (1) KR100894359B1 (https=)
CN (1) CN100529076C (https=)
AR (1) AR035560A1 (https=)
AT (1) ATE389019T1 (https=)
AU (2) AU780163B2 (https=)
CA (1) CA2388562C (https=)
DE (1) DE60038304T3 (https=)
ES (1) ES2300276T5 (https=)
HK (1) HK1044170B (https=)
HU (1) HU230679B1 (https=)
IL (1) IL148300A0 (https=)
MX (1) MXPA02002684A (https=)
WO (1) WO2001018051A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007202362B2 (en) * 1999-09-03 2011-06-23 Merck Sharp & Dohme Corp. Mammalian receptor proteins; related reagents and methods
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US6756481B2 (en) 2000-05-10 2004-06-29 Schering Corporation IL-23 receptor binding compositions
WO2004042009A2 (en) 2002-10-30 2004-05-21 Genentech, Inc. Inhibition of il-17 production
WO2004058178A2 (en) 2002-12-23 2004-07-15 Schering Corporation Uses of mammalian cytokine; related reagents
US7282204B2 (en) 2003-03-10 2007-10-16 Schering Corporation Uses of IL-23 agonists and antagonists; related reagents
CN101052726A (zh) 2003-05-09 2007-10-10 森托科尔公司 IL-23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途
EP1522858A1 (en) * 2003-10-10 2005-04-13 Jean-Christophe Roegel Methods for selecting compounds using antibodies with activity as agonist, antagonist or allosteric modulators
WO2005108425A1 (en) * 2004-05-10 2005-11-17 Cytos Biotechnology Ag Il-23 p19 antigen array and uses thereof
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US7820168B2 (en) 2004-12-20 2010-10-26 Schering Corporation Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17
SI2452694T1 (sl) 2005-06-30 2019-05-31 Janssen Biotech, Inc. Protitelesa proti-IL-23, sestavki in postopki uporabe
DE602006015830D1 (de) 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
PT1931710T (pt) 2005-08-31 2017-03-28 Merck Sharp & Dohme Anticorpos anti-il-23 manipulados
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
PL1966238T3 (pl) 2005-12-30 2012-09-28 Merck Patent Gmbh Warianty interleukiny-12p40 o polepszonej stabilności
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Il-23拮抗劑於治療感染之用途
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−il−23p19抗体
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
NZ579251A (en) 2007-02-28 2012-06-29 Schering Corp Engineered anti-il-23r antibodies
CA2679400A1 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
EP2650311A3 (en) 2007-11-27 2014-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
JPWO2009133863A1 (ja) * 2008-04-28 2011-09-01 国立大学法人浜松医科大学 Ep1アゴニストを含有してなる免疫増強剤
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
EP2850093B1 (en) 2012-01-27 2019-01-09 The Board of Trustees of the Leland Stanford Junior University Therapeutic il-13 polypeptides
PL3326649T3 (pl) 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
CN104619334A (zh) 2012-08-09 2015-05-13 利兰斯坦福初级大学董事会 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
WO2014171721A1 (ko) * 2013-04-16 2014-10-23 가톨릭대학교 산학협력단 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도
KR101625112B1 (ko) 2013-04-16 2016-05-27 가톨릭대학교 산학협력단 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도
EP3049526B1 (en) 2013-09-24 2021-02-24 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
EA202193002A2 (ru) 2014-09-03 2022-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23a и фно-альфа, и его применение
JP6219875B2 (ja) * 2015-04-10 2017-10-25 株式会社スクウェア・エニックス ネットワークゲームシステム、ゲーム装置及びプログラム
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗lag3抗体の製剤および抗lag3抗体と抗pd-1抗体との共製剤
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3694558B1 (en) 2017-10-10 2024-04-10 Medicenna Therapeutics Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
US12590133B2 (en) 2018-06-01 2026-03-31 The Board Of Trustees Of The Leland Stanford Junior University IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof
WO2020081408A1 (en) 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations of anti-rsv antibodies and methods of use thereof
MX2021004928A (es) 2018-10-31 2021-06-08 Merck Sharp & Dohme Llc Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
IL283192B2 (en) 2018-11-20 2025-10-01 Janssen Biotech Inc A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク,インコーポレーテツド Il-23及びtnfアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CN114317430A (zh) * 2021-12-28 2022-04-12 河北银丰鼎诚生物技术有限公司 一种适用于脐血来源免疫细胞扩增的培养液

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69034249T2 (de) * 1989-12-22 2008-05-29 F. Hoffmann-La Roche Ag Monoklonale Antikörper spezifisch für den zytotoxischen Lymphozyten-Reifefaktor
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5853721A (en) 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
EP0956301A2 (en) * 1996-10-18 1999-11-17 Valentis Inc. Il-12 gene expression and delivery systems and uses
ZA986596B (en) * 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
WO1999040195A1 (en) * 1998-02-06 1999-08-12 Schering Corporation Mammalian receptor proteins; related reagents and methods

Similar Documents

Publication Publication Date Title
JP2009268467A5 (https=)
JP2008536483A5 (https=)
JP2012532601A5 (https=)
JP2005120106A5 (https=)
JP2010065037A5 (https=)
JP2018138049A5 (https=)
JP2022503959A5 (https=)
JP2011528896A5 (https=)
JP2009225798A5 (https=)
JP2013048638A5 (https=)
JP2006149406A5 (https=)
JP2007175057A5 (https=)
WO2006119987A3 (en) Recombinant n-glycosylated proteins from procaryotic cells
RU2016106583A (ru) Пептиды, способные реактивировать мутанты р53
JP2010227108A5 (https=)
JP2011177189A5 (https=)
JP2010512160A5 (https=)
JP2010532656A5 (https=)
PH12012502272A1 (en) Biological materials related to her3
JP2016527891A5 (https=)
JP2008538183A5 (https=)
JP2011530309A5 (https=)
JP2011528895A5 (https=)
JP2014529399A5 (https=)
JP2012529293A5 (https=)